(Q37390644)

20 August 2017

1 reference

title

Esomeprazole: a proton pump inhibitor (English)

1 reference

20 August 2017

1 reference

Ravi Vachhani

1

1 reference

20 August 2017

Gregory Olds

series ordinal

2

1 reference

20 August 2017

Vic Velanovich

series ordinal

3

1 reference

20 August 2017

publication date

1 February 2009

1 reference

Expert Review of Gastroenterology & Hepatology

20 August 2017

published in

1 reference

20 August 2017

volume

3

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

15-27

1 reference

Epidemiology of gastro-oesophageal reflux disease: a systematic review

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Epidemiology and natural history of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Gastroesophageal reflux among different racial groups in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Prevalence and incidence of peptic ulcer disease in a Danish County--a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

The burden of gastrointestinal and liver diseases, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Drug interactions between HIV protease inhibitors and acid-reducing agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Drug interactions between proton pump inhibitors and antiretroviral drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

The pharmacology of the gastric acid pump: the H+,K+ ATPase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Oral esomeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Reanalysis of intragastric pH results based on updated correction factors for Slimline and Zinetics 24 single-use pH catheters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Potential uses of intravenous proton pump inhibitors to control gastric acid secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole 40 mg i.v. provides faster and more effective intragastric acid control than pantoprazole 40 mg i.v.: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Intravenous Esomeprazole 40mg is Effective for the Control of Intragastric Acid Levels Whether Given as a 3-Minute Injection or a 30-Minute Infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Treatment of chronic posterior laryngitis with esomeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Clinical trial: healing of NSAID-associated gastric ulcers in patients continuing NSAID therapy - a randomized study comparing ranitidine with esomeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Pharmacokinetic study of esomeprazole in patients with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Pharmacokinetic study of esomeprazole in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Long-term proton pump inhibitor therapy and risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Vitamin B12 levels during prolonged treatment with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.3.1.15

21 January 2018

Identifiers

DOI

10.1586/17474124.3.1.15

1 reference

20 August 2017

1 reference